VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Recommendations for treatment discontinuation in CML

Francois-Xavier Mahon, MD, PhD, University of Bordeaux, Bordeaux, France, outlines the latest recommendations for tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic myeloid leukemia (CML), explaining how to increase the number of candidates for treatment-free remission (TFR). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter